Neuro-Oncology and Positron Emission Tomography: “Just Can’t Get Enough”

Muoio, Barbara; Espeli, Vittoria; Treglia, Giorgio

doi:10.3390/cancers15194739

Cancers

2023

DOI: 10.3390/cancers15194739

|View full text |Cite

Neuro-Oncology and Positron Emission Tomography: “Just Can’t Get Enough”

Barbara Muoio,

Vittoria Espeli,

Giorgio Treglia

Abstract: Imaging has a pivotal role in neuro-oncology for the management of primary and secondary brain tumors [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Intra-arterial administration of PSMA-targeted radiopharmaceuticals for brain tumors: is the era of interventional theranostics next?

Da Ros,

Filippi,

Garaci

2024

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Intra-arterial administration of PSMA-targeted radiopharmaceuticals for brain tumors: is the era of interventional theranostics next?

Da Ros,

Filippi,

Garaci

2024

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Immuno-PET for Glioma Imaging: An Update

De Feo,

Granese,

Conte

et al. 2024

Applied Sciences

View full text Add to dashboard Cite

Despite significant advances in glioma diagnosis and treatment, overall outcomes remain suboptimal. Exploring novel therapeutic avenues show promise in advancing the field. Theranostics, an evolving discipline integrating diagnosis and therapy, emerges as a particularly auspicious approach. However, an unmet need exists for glioma-associated biomarkers as theranostic targets. Immuno-positron emission tomography (Immuno-PET), a pioneering method uniting PET diagnostic precision with antibody specificity, holds potential for identifying cancer-associated biomarkers. This review aims to provide an updated overview of immuno-PET applications in gliomas. Notably, [44Sc]-CHX-A″-DTPA-Cetuximab-Fab targeting Epidermal Growth Factor Receptor (EGFR) has displayed promise in glioma xenografts, enabling potential imaging at 4 h post-injection. Similarly, [89Zr]-bevacizumab targeting vascular endothelial growth factor (VEGF) yielded encouraging results in preclinical models and a pioneering clinical trial for pediatric patients with diffuse intrinsic pontine glioma (DIPG). Several cell differentiation markers, including CD146, indicative of tumor aggressiveness, and CD11b, reflecting tumor-associated myeloid cells (TAMCs), proved effective targets for immuno-PET. Additionally, immuno-PET directed at prostate-specific antigen (PSMA) demonstrated efficacy in imaging glioma-associated neovasculature. While holding promise for precise diagnosis and treatment guidance, challenges persist in achieving target specificity and selecting suitable radionuclides. Further studies are imperative to advance the field and bridge a translational gap from bench to bedside.

show abstract

“Rosary Sign” at Somatostatin Receptor PET in a Case of Recurrent Meningioma

Iacovitti,

Bosetti,

Muoio

et al. 2024

Diagnostics

View full text Add to dashboard Cite

We present the case of a 60-year-old male with recurrent atypical meningioma in the right parietal lobe, previously treated with surgery and radiation therapy. Magnetic resonance imaging (MRI) performed 5 years after radiation therapy suggested a possible recurrence. A somatostatin receptor positron emission tomography/computed tomography (SR-PET/CT) scan with Gallium-68 DOTATATE was performed to confirm this suspicion. SR-PET/CT confirmed the presence of recurrent meningioma, showing a novel “rosary sign” with multiple adjacent areas of focal tracer uptake along the resection margins of the previous surgical site in the right parietal region. This novel imaging pattern improved diagnostic accuracy by detailing disease extent and identifying additional lesions not visible via MRI. Given the failure of prior treatments and high SR expression, peptide receptor radionuclide therapy (PRRT) was proposed as a therapeutic option for the patient.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Neuro-Oncology and Positron Emission Tomography: “Just Can’t Get Enough”

Abstract: Imaging has a pivotal role in neuro-oncology for the management of primary and secondary brain tumors [...]

Cited by 3 publications

References 21 publications

Intra-arterial administration of PSMA-targeted radiopharmaceuticals for brain tumors: is the era of interventional theranostics next?

Intra-arterial administration of PSMA-targeted radiopharmaceuticals for brain tumors: is the era of interventional theranostics next?

Immuno-PET for Glioma Imaging: An Update

“Rosary Sign” at Somatostatin Receptor PET in a Case of Recurrent Meningioma

Contact Info

Product

Resources

About